Company Filing History:
Years Active: 1992-1996
Title: Innovations of Bjorn A Nexo
Introduction
Bjorn A Nexo is a notable inventor based in Soborg, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of tissue plasminogen activator (t-PA) analogs. With a total of two patents to his name, Nexo's work focuses on enhancing the specificity and efficacy of these important pharmaceutical compounds.
Latest Patents
Nexo's latest patents include innovative approaches to tissue plasminogen activator analogs. One patent describes t-PA analogs that contain the growth factor domain of native t-PA, with at least one cysteine residue replaced by another amino acid. These analogs may also include various substitutions and modifications, along with pharmaceutical compositions that contain one or more of the t-PA analogs combined with a physiologically acceptable carrier or diluent. Another patent highlights modified t-PA analogs that exhibit greater specificity for fibrin than native t-PA. This innovation involves replacing the K1 domain of native t-PA with another kringle domain, which mediates the binding of the analog to fibrin. The kringle in this case contains six cysteine residues, and similar to the previous patent, these analogs may also include a variety of substitutions and modifications.
Career Highlights
Bjorn A Nexo is associated with Zymogenetics, Inc., where he continues to advance his research and development efforts. His work has been instrumental in the field of pharmaceuticals, particularly in creating more effective treatments for conditions requiring fibrinolysis.
Collaborations
Nexo collaborates with esteemed colleagues such as Eileen R Mulvihill and Shinji Yoshitake, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Bjorn A Nexo's contributions to the field of biotechnology through his patents on tissue plasminogen activator analogs demonstrate his commitment to advancing medical science. His work not only enhances our understanding of these compounds but also paves the way for improved therapeutic options.